NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

This action was surfaced by Law.com Radar, which delivers real-time alerting on new litigation across more than 2,600 state and federal courts. Click here to get started and be first to act on ...

The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...

GSK investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the filed complaint, defendants ...

GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February ...

or contact Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities ...

THE LAWSUIT: A class action securities lawsuit was filed against GSK plc that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 5 ...